When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more. Read more
Despite access to free treatment within the National Health Service, patients in the most deprived areas were 55% less likely to receive targeted therapies, biologic treatments, and immunotherapy compared to residents in the least deprived areas. Read more
Advocacy group says its annual research events are key to its mission: Making EGFR-mutated lung cancer a manageable chronic disease. Read more
Advocate Terri Ann DiJulio knows the stigma associated with smoking must end if more lung cancer patients are to be diagnosed and treated early. The first step is talking about it. Read more
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning. Read more
Studies that don’t show survival benefit with more frequent surveillance won’t convince patients they’re better off without scans. Even if regularly scheduled scans don’t help patients live longer, they do help them live better. Read more
Patient Advocates Committee Chair Jill Feldman said ensuring the patient voice is present in research helps to improve the work being done to reduce the burden of lung cancer worldwide. Read more
Even when treatment costs are covered, the majority of lung cancer patients experience increased expenses and/or reduced income following their diagnoses. Read more
A real-world look at diagnostic-therapeutic pathways explores how they may help provide optimal, innovative care without ballooning costs. Read more
Growing treatment options for patients with late-stage lung cancer bring hope—and challenges. Read more